Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: A network meta-analysis accounting for differences in trial designs

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 5, 2015, Pages 693-700

  Thorlund, Kristian ^a,b   Druyts, Eric ^a,c   Toor, Kabirraaj ^a,c   Mills, Edward J ^a  

^a Redwood Outcomes   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

adalimumab; golimumab; infliximab; network meta analysis; ulcerative colitis

Indexed keywords

ADALIMUMAB; GOLIMUMAB; INFLIXIMAB; PLACEBO; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; HEALING; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; REMISSION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; COMPARATIVE EFFECTIVENESS RESEARCH; HUMANS; INDUCTION CHEMOTHERAPY; INFLIXIMAB; MAINTENANCE CHEMOTHERAPY; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84928548098     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1024657     Document Type: Article

References (16)

1. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76
3. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95.quiz e14-5
4. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109.e1
5. Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.e1-3
6. Lv R, Qiao W, Wu Z, et al. Tumor necrosis factor alpha blocking agentsas treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One 2014; 9: e86692
7. Thorlund K, Druyts E, Mills EJ, et al. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: An indirect treatment comparison meta-analysis. J Crohns Colitis 2014; 8(7): 571-81
8. Stidham R, Lee T, Higgins P, et al. Systematic review with network metaanalysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014; 39: 660-71
9. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014; 160: 704-11
10. Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802
11. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11
12. Reinisch W, Sandborn WJ, Panaccione R, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013; 19: 1700-9
13. Thorlund K, Druyts E, Toor K, et al. Incorporating alternative design clinical trials in network meta-analyses. Clinical epidemiology 2015; 7: 29-35
14. Dias S, Welton N, Sutton A, et al NICE DSU Technical Support Document 2 -A generalised linear modelling framework fro pairwise and network meta-analysis of randomised controlled trial 2011
15. Thorlund K Thabane L Mills E. Modeling heterogeneity variances in multiple treatment comparison meta-analysis - are informative priors the better solution?. BMC Med Res Methodol 2012 13
16. Turner R, Davey J, Clarke M, et al. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane database of systematic reviews. Int J Epidemiol 2012; 41: 818-27